We're back from the Digestive Disease Week (DDW) medical conference. As always, it provides a wealth of information from researchers and industry about IBS and other digestive disorders. A few tidbits of what we learned. We will be posting a complete summary sometime next week.
- Gut microbiota (bacteria) has a complex relationship with us. Diet is a major determinant of gut microbiota. There were murmurs that food may play an important role in IBS despite doctors denying that food plays any role.
- Small Intestinal Bacteria Overgrowth (SIBO) may be far more rare in IBS than what was believed.
- Most burdensome cormorbidities with IBS are lower back pain, major depression, general anxiety disorder, insomnia
- The first year after you are diagnosed with IBS is the time when you seek most medical services.
- If your bloating and distension do not follow a cycle of getting worse during the day and more painful at night, followed by return to normal the next morning than it's a red flag and needs further examination by a doctor
- Plecanatide is a new IBS-C (IBS w/constipation) medication that is entering Phase-3 clinical studies. The safety profile is impressive.
- A new prescription medical food for IBS-D (IBS with diarrhea) with be on the market in July in the US - EnteraGam™ (serum-derived bovine immunoglobulin/protein isolate; SBI). It is a very different kind of treatment. Side effects are virtually non-existent unless you are allergic to beef.
Founder, IBS Self Help and Support Group